Patrick Campbell

Results of a study from investigators at the Retina Center of Minnesota found that same-day injections were preferred by more than 97% of patients.

Manjot Gill, MD, discusses the results of her study which found early diagnosis and treatment of neovascular age-related macular degeneration could help save a patient’s vision.

Artificial intelligence could be the future of detecting certain diseases in the eye, after a study presented at ASRS 2019 found that the EyeArt system was effective in detecting referable diabetic retinopathy from images.

Investigators presented 36-month results of a study which found that treatment with a single intravitreal injection of the FAi provided anti-inflammatory treatment for 3 years in patients with non-infectious uveitis affecting the posterior segment of the eye

Additional analyses of the phase 2 BOULEVARD trial, which found faricimab not only led to improved best-corrected visual acuity and central subfield thickness from baseline, but also provided anatomical benefits and displayed a potential for extended durability compared to anti-VEGF monotherapy, were presented during ASRS 2019

Medical Director of the Macular Degeneration Association discusses how the evolution of anti-VEGF treatments has changed the landscape of AMD care and the lives of patients.

Results of a study presented at ASRS 2019 found that biweekly anti-VEGF dosing may be an effective treatment for treating nAMD refractory to standard monthly dosing.

While often seen in a negative light, some physicians have found ways to incorporate electronic medical records to improve their practice.

Eleonora Lad, MD, PhD, presented results of a post-hoc analysis evaluating the impact of baseline characteristics on lesion progression in patients receiving APL-2 for geographic atrophy at ASRS 2019.

Carl Regillo, MD, of Wills Eye, and Michael Stewart, of the Mayo Clinic, discuss changes they would like to see in their speciality at ASRS 2019.

W. Lloyd Clark, MD, of Palmetto Retina Center, discusses clinical implications of the 52-week PANORAMA results, which found treatment with intravitreal aflibercept injections could reverse disease progression in patients with moderately severe to severe NPDR.

Jeffrey Heier, MD, presented 24-month results of the PRO-CON study, which found no statistical difference in conversion rates in fellow eyes regardless of prophylactic treatment with aflibercept injections, at ASRS 2019.

Ajay Kuriyan, MD, discusses what he warns patients to be aware of when seeking out treatment from stem cell therapies and why he believes other physicians should as well.

LADDER study results presented at ASRS revealed efficacy of the PDS was equal to that of monthly ranibizumab.

An oral therapy for aged-related macular degeneration could be on the horizon after displaying efficacy in a recent phase 2 study.

Carl Regillo, MD, who presented 96-week data of brolucizumab at ASRS 2019, discusses how brolucizumab could impact care of wAMD in a real-world setting.

More patients undergoing long-term use anti-VEGF therapy saw improvements in visual acuity than saw declines after 10 years.

Investigators from Wills Eye and Retina Consultants of Austin presented 96-week data from the HAWK and HARRIER trials at ASRS 2019.

Peter Kaiser, MD, presented data from a phase 2 trial examining the safety and efficacy of risuteganib at ASRS 2019.

W. Lloyd Clark, MD, discusses the approaches he uses in his clinical practice to reduce patient noncompliance — specifically, when treating diabetic macular edema.

As physician burnout becomes a more common issue, physician across an array of fields find themselves discussing and formulating ways to circumvent burnout.

Physician from Palmetto Retina Center on deciding between aflibercept, ranibizumab, and avastin for treatment of DME.

A recent study published in the journal of the European Journal of Endocrinology found significant benefits of vitamin D supplementation on the development and progression of diabetes.

Investigators examining more than 1000 university students found that those using a smartphone more than 5 hours per day had a 43% increased risk of obesity.

Investigators from Brigham and Women's Hospital found no difference in mortality rate among procedures, even those that coincide with the start of resident training.

With approval, Baqsimi, which was approved for adults and children as young as 4, becomes the first approved treatment of hypoglycemia that can be administered without an injection.

In a recent study, investigators from Johns Hopkins found that risks of peripheral artery disease remains elevated for 30 years after smoking cessation.

Results of the SHINE trial show no significant difference between standard and intensive treatment of hyperglycemia on functional outcomes following acute ischemic stroke.

A recent study has found that the cost and accessibility of PCSK9 inhibitors has created problems for patients seeking an effective treatment for their hypercholesterolemia.

Investigators from the University of Duke School of Medicine compared results of the PROSPER Study and found results supporting the use of DOACs over warfarin in older patients following ischemic stroke.